Rosiglitazone Does Not Show Major Hidden Cardiotoxicity in Models of Ischemia/Reperfusion but Abolishes Ischemic Preconditioning-Induced Antiarrhythmic Effects in Rats In Vivo

Clinical observations are highly inconsistent with the use of the antidiabetic rosiglitazone regarding its associated increased risk of myocardial infarction. This may be due to its hidden cardiotoxic properties that have only become evident during post-marketing studies. Therefore, we aimed to inve...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Bennet Y. Weber, Gábor B. Brenner, Bernadett Kiss, Tamás G. Gergely, Nabil V. Sayour, Huimin Tian, András Makkos, Anikó Görbe, Péter Ferdinandy, Zoltán Giricz
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	MDPI AG 2022-08-01
Schriftenreihe:	Pharmaceuticals
Schlagworte:	rosiglitazone hidden cardiotoxicity ischemic preconditioning I/R injury model diabetes thiazolidinedione
Online-Zugang:	https://www.mdpi.com/1424-8247/15/9/1055
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!